| Literature DB >> 33847017 |
Sonja Neuser1, Barbara Brechmann2,3, Gali Heimer4,5, Ines Brösse3, Susanna Schubert1, Lauren O'Grady6, Michael Zech7,8, Siddharth Srivastava2, David A Sweetser6, Yasemin Dincer9,10, Volker Mall9,11, Juliane Winkelmann7,8,12,13, Christian Behrends13, Basil T Darras14, Robert J Graham15, Parul Jayakar16, Barry Byrne17, Bat El Bar-Aluma4,5, Yael Haberman4,5,18, Amir Szeinberg4,5, Hesham M Aldhalaan19, Mais Hashem19, Amal Al Tenaiji20, Omar Ismayl20, Asma E Al Nuaimi20, Karima Maher20, Shahnaz Ibrahim21, Fatima Khan21, Henry Houlden22, Vijayalakshmi S Ramakumaran23, Alistair T Pagnamenta24, Jennifer E Posey25, James R Lupski25,26,27,28, Wen-Hann Tan29, Gehad ElGhazali20, Isabella Herman25,27,30, Tatiana Muñoz31, Gabriela M Repetto31, Angelika Seitz32, Mandy Krumbiegel33, Maria Cecilia Poli26,31, Usha Kini23, Stephanie Efthymiou22, Jens Meiler34,35, Reza Maroofian22, Fowzan S Alkuraya19,36, Rami Abou Jamra1, Bernt Popp1, Bruria Ben-Zeev4,5, Darius Ebrahimi-Fakhari2.
Abstract
Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.Entities:
Keywords: Human Phenotype Ontology; TECPR2; neurodevelopmental disorder; sensory autonomic neuropathy; spastic paraplegia
Mesh:
Substances:
Year: 2021 PMID: 33847017 DOI: 10.1002/humu.24206
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878